INNOVATIONS / NOVOTECT®️

NOVOTECT®️ IS A BLOOD-BASED TEST FOR THE EARLY DIAGNOSIS OF BREAST CANCER.

BREAST CANCER IS THE MOST COMMON INVASIVE CANCER IN WOMEN WORLDWIDE, WITH ALMOST 1.5 MILLION WOMEN DIAGNOSED IN 2010 ALONE. 

NovoTect®️ is a blood-based liquid biopsy test to detect breast cancer based on the epigenetic differences between breast cancer and healthy individuals. NovoTect®️ is the first-ever test to stratify Asian patients regardless of sub-type and stage of breast cancer.

 

NovoTect®️ can be used to augment mammography and ultrasound scans, where these diagnostic tools are inconclusive to support diagnosis, especially in cases where early cancers cannot be detected using invasive, poor performing and uncomfortable tests.

The fundamental nature of the epigenetic mechanisms monitored by the NovoTect®️ technology allows for the detection of changes in DNA methylation irrespective of the abundance or stability of RNA and protein products, which are common targets in other diagnostic tests. 

 

NovoTect®️ monitors upstream changes in epigenetic targets, which are highly stable relative to less stable downstream targets such as RNA and proteins. This offers a significant advantage relative to RNA and protein-based technologies, which are affected by degradation and low copy numbers of the monitored targets.

KEY BENEFITS OF NOVOTECT®️

01

ADVANTAGES AGAINST RNA AND PROTEIN BASED DIAGNOSTIC PRODUCTS 

The fundamental nature of the epigenetic mechanisms monitored by the NovoTect®️ technology is that it can detect and identify changes in gene expression irrespective of the abundance or stability of RNA and protein products. This offers a significant advantage against RNA and protein-based technologies, which are affected by degradation and the low copy numbers of the monitored targets.

02

HIGH STABILITY

The fundamental nature of the epigenetic targets monitored by the NovoTect®️ technology display high stability and a low degradation rate, because of the unique biochemical properties displayed by particular epigenetic methylation on particular location of long chain of DNAs. The uniqueness of our proprietary biomarkers is that the epigenetic profiles in breast cancer are categorically different that in healthy breast. Therefore, very few copies of cancer DNA can be detected on a high background of normal DNA using next -generation sequencing methods. 

03

INCREASE SENSITIVITY

The DNA-based read-out of the NovoTect®️ technology offers well-established methods of signal amplification. The uniqueness of our proprietary DNA methylation biomarkers is that the profiles in breast cancer are categorically different that in healthy breast. Therefore, very few copies of cancer DNA can be detected on a high background of normal DNA, this would increase the sensitivity of cancer detection. The technology takes advantage of next-generation sequencing techniques and utilises that technique to monitor novel epigenetic targets.  

04

EPIGENETIC TARGETS

The epigenetic mechanisms monitored by the NovoTect®️ technology offers highly informative statistically significant read-outs from a minimal number of targets for each test. A validated large-scale trial for a number of genes implicated in the onset and development of breast cancer provides a very high sensitivity and specificity of correct patient stratification (>97%) on only 3 genes (4 epigenetic targets).

05

CLINICALLY FRIENDLY

The NovoTect®️ test can utilise standard blood sample collection workflow to collect clinical samples from patients. In addition, all standard types of clinical samples practiced today by clinicians around the world, such as paraffin embedded fixed and frozen tissues are also applicable.

The NovoTect®️ will be available in Q3 2021.

INEX INNOVATE PTE. LTD

1 Science Park Road

#04-10 The Capricorn

Singapore 117528

CALL  +65 6773 0698

FAX   +65 6873 0240

© 2020 INEX INNOVATE PTE LTD